Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03554642
Other study ID # BRC532
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2016
Est. completion date December 2019

Study information

Verified date January 2020
Source Burke Medical Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical study will involve up to 30 ischemic stroke inpatients during their stay at Burke Rehabilitation Hospital. Participants will be randomized to receive 30 additional minutes of therapy every day, for a total of 2 weeks (14 days). One group will receive 30 minutes of standard physical therapy focused on pre-gait or gait training activities, while the experimental group will receive 30 minutes of Walkbot with Augmented Reality. Both groups will receive the same time in therapy aimed at gait training.


Description:

This controlled clinical study will involve 30 ischemic stroke inpatients during their stay at Burke Rehabilitation Hospital (typical inpatient arrives 7 days post-stroke and is admitted for ~16 days).

Stroke inpatients will be sequentially randomized into one of two groups within the first week after admission. Both Groups will receive 30 additional minutes of therapy every day, for a total of 2 weeks (14 days). Group A will enroll 15 patients who will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days). Group B will enroll 15 patients who receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days). Both groups will receive the same time in therapy aimed at gait training. The extra therapy group will not exceed more than 15 minutes of pregait training before starting to walk the patient, and will spend at least 15 minutes doing active gait training per session. Patients in the treatment group will receive 30 minutes of total training on the Walkbot, excluding setup time. Primary and secondary outcomes will be collected, prior to the first therapy session. Follow up outcome measures will be collected within two days after the final interventional (study) therapy session. The amount of therapists needed for each session will be logged for every patient after Walkbot training or extra physical therapy. Borg rating of perceived exertion will be taken after each session from the patients, and NASA Task Load Index will be completed by the therapists (ie therapist load). Outcomes will be analyzed for significant differences.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 2019
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- Cortical/subcortical ischemic stroke

- 1st time clinical stroke presentation, or prior stroke with no residual deficits affecting ambulation

- Ability to follow 2 step commands

- Fugl Meyer Sensory Score > 2

- Suitability for gait training as assessed clinically (ability to ambulate at least one step with a device/assistance)

- Height 132 cm- 200 cm; hip-knee joint length: 33 cm- 48 cm; knee joint-foot: 33 cm-48 cm

Exclusion Criteria:

- Cerebellar/brainstem stroke

- Body weight >135 kg

- Uncontrolled high blood pressure (stage 2) higher than 160 (systolic)/ 100 (diastolic)

- Cardiopulmonary system impairments affecting the ambulation test.

- Integumentary impairment: skin breakdown and bedsore around the loading area of the suspension belt

- No previous robotic intervention for ambulation training

- Significant and persistent mental illness.

- A fixed contracture or deformity in lower extremity.

- Bone instability (non-consolidated fractures, unstable spinal column, severe osteoporosis necessitating treatment with bisphosphonates).

- Other neurodegenerative disorders (Amyotrophic lateral sclerosis, Parkinsonian disorder).

- Modified Ashworth scale >3 in affected leg.

- Significant back or leg pain that creates an inability to tolerate movement.

- Decreased sensation that will impair patient's ability to percept whether the device is properly fitted

- Aphasia of a degree that would prevent the patient from communicating discomfort.

- Inability to tolerate the Walkbot device or ambulation therapy

Study Design


Intervention

Device:
Walkbot
Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
Behavioral:
Physical Therapy
30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).

Locations

Country Name City State
United States Burke Medical Research Institute White Plains New York

Sponsors (2)

Lead Sponsor Collaborator
Burke Medical Research Institute P&S Mechanics Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fugl Meyer Assessment Lower extremity impairment measure Discharge evaluation (within 2 days after last session)
Secondary NIH Stroke Scale Quantitative measure of stroke-related neurological deficit; The scale is comprised of 11 items with a maximal score of 42 and minimum of 0. Higher scores indicate severe stroke. Baseline assessment and discharge evaluation within 2 days after last session
Secondary Modified Ashworth Scale Measure of spasticity; Each muscle assessed is scored between 0-4, with 4 indicating rigid limbs or very severely affected. Baseline assessment and discharge evaluation within 2 days after last session
Secondary Functional Ambulation Classification Clinical measure of mobility Baseline assessment and discharge evaluation within 2 days after last session
Secondary 6 Minute Walk Test Measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes. Baseline assessment and discharge evaluation within 2 days after last session
Secondary 10 Meter Walk Test Examines gait speed Baseline assessment and discharge evaluation within 2 days after last session
Secondary Timed Up and Go Assesses mobility in both static and dynamic balance Baseline assessment and discharge evaluation within 2 days after last session
Secondary Berg Balance Scale Assesses balance during a series of 14 tasks; higher scores indicate greater independence. Baseline assessment and discharge evaluation within 2 days after last session
Secondary Burke Lateropulsion Scale 5 item scale measures lateropulsion or "Pusher Syndrome" by assessing reaction to change in postural position; 0 = no lateropulsion, 17= maximum score. Baseline assessment and discharge evaluation within 2 days after last session
Secondary Beck Depression Inventory 21 question, multiple choice, self-report inventory to assess depression; score of 0= minimal depression, 63= severe depression. Baseline assessment and discharge evaluation within 2 days after last session
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02924168 - Radial Shock Waves for Functional Disability in Stroke N/A